NORDIC NANOVECTOR ASA has a total of 35 patent applications. It decreased the IP activity by 36.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), Australia and United States. Its main competitors in its focus markets pharmaceuticals and biotechnology are ADC THERAPEUTICS S RL, BERLIN CHEMIE AG and IMUNAMI LABORATORIES PTE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | Australia | 4 | |
#3 | United States | 4 | |
#4 | China | 3 | |
#5 | Hong Kong | 3 | |
#6 | Israel | 3 | |
#7 | Republic of Korea | 2 | |
#8 | Mexico | 2 | |
#9 | WIPO (World Intellectual Property Organization) | 2 | |
#10 | Brazil | 1 | |
#11 | Canada | 1 | |
#12 | Japan | 1 | |
#13 | New Zealand | 1 | |
#14 | Philippines | 1 | |
#15 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Dahle Jostein | 23 |
#2 | Larsen Roy H | 15 |
#3 | Repetto-Llamazares Ada | 11 |
#4 | Turner Simon | 10 |
#5 | Patzke Sebastian | 4 |
#6 | Malenge Marion Masita | 4 |
#7 | Pouget Jean Pierre | 4 |
#8 | Heyerdahl Helen | 4 |
#9 | Pichard Alexandre | 4 |
#10 | Syljuåsen Randi | 3 |
Publication | Filing date | Title |
---|---|---|
CN111372613A | Radioimmunoconjugates in combination with other drugs for the treatment of non-hodgkin's lymphoma | |
WO2018050851A1 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
EP3332813A1 | Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody |